CO6430439A2 - Agonistas del receptor de esfingosina -1- fosfato - Google Patents

Agonistas del receptor de esfingosina -1- fosfato

Info

Publication number
CO6430439A2
CO6430439A2 CO12027713A CO12027713A CO6430439A2 CO 6430439 A2 CO6430439 A2 CO 6430439A2 CO 12027713 A CO12027713 A CO 12027713A CO 12027713 A CO12027713 A CO 12027713A CO 6430439 A2 CO6430439 A2 CO 6430439A2
Authority
CO
Colombia
Prior art keywords
compounds
phosphate
receptor agonists
disclosed
diseases
Prior art date
Application number
CO12027713A
Other languages
English (en)
Inventor
John L Gilmore
James E Sheppeck
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of CO6430439A2 publication Critical patent/CO6430439A2/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

Se divulgan compuestos de fórmula (I):o un estereoisómero o una sal farmacéuticamente aceptable del mismo, en la que:Q es un grupo heteroarilo monocíclico de 5 miembros;W es CH2, O, o NH; y R1, R2, R3, R4, R5, R6, m, n, t, y x se definen en la presente descripción. También se divulgan procedimientos de uso de los compuestos como agonistas selectivos para el receptor S1P1 acoplado a proteína G, y composiciones farmacéuticas que comprenden los compuestos. Estos compuestos son útiles en el tratamiento, la prevención o la ralentización de la progresión de enfermedades o trastornos en una variedad de áreas terapéuticas, tales como enfermedades autoinmunitarias y enfermedad vascular.
CO12027713A 2009-08-07 2012-02-16 Agonistas del receptor de esfingosina -1- fosfato CO6430439A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US23205409P 2009-08-07 2009-08-07

Publications (1)

Publication Number Publication Date
CO6430439A2 true CO6430439A2 (es) 2012-04-30

Family

ID=43029859

Family Applications (1)

Application Number Title Priority Date Filing Date
CO12027713A CO6430439A2 (es) 2009-08-07 2012-02-16 Agonistas del receptor de esfingosina -1- fosfato

Country Status (19)

Country Link
US (1) US8399451B2 (es)
EP (1) EP2462139B1 (es)
JP (1) JP5602230B2 (es)
KR (1) KR20120108963A (es)
CN (1) CN102548989A (es)
AR (1) AR077819A1 (es)
AU (1) AU2010279354A1 (es)
BR (1) BR112012002824A2 (es)
CA (1) CA2770194A1 (es)
CL (1) CL2012000326A1 (es)
CO (1) CO6430439A2 (es)
EA (1) EA201270266A1 (es)
ES (1) ES2533095T3 (es)
MX (1) MX2012001160A (es)
PE (1) PE20120732A1 (es)
SG (1) SG177691A1 (es)
TW (1) TW201109323A (es)
WO (1) WO2011017578A1 (es)
ZA (1) ZA201200641B (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2667545A1 (en) * 2006-10-25 2008-05-02 Neurosearch A/S Oxadiazole and thiadiazole compounds and their use as nicotinic acetylcholine receptor modulators
CN103119038B (zh) * 2010-04-23 2016-05-04 百时美施贵宝公司 作为1-磷酸鞘氨醇1受体激动剂的4-(5-异噁唑基或5-吡唑基-1,2,4-噁二唑基-3-基)扁桃酰胺
CN103124727B (zh) 2010-07-20 2015-03-25 百时美施贵宝公司 取代的3-苯基-1,2,4-噁二唑化合物
WO2012040532A1 (en) 2010-09-24 2012-03-29 Bristol-Myers Squibb Company Substituted oxadiazole compounds and their use as s1p1 agonists
JP2013544811A (ja) * 2010-11-03 2013-12-19 ブリストル−マイヤーズ スクイブ カンパニー 自己免疫疾患および血管疾患の治療用のs1p1アゴニストとしての複素環式化合物
US9115054B2 (en) 2013-02-21 2015-08-25 Bristol-Myers Squibb Company Tetrahydronaphthalenyl compounds useful as sipi agonists
UY36274A (es) 2014-08-20 2016-02-29 Bristol Myers Squibb Company Una Corporación Del Estado De Delaware Compuestos bicíclicos sustituidos como agonistas selectivos de la actividad del receptor s1p1 acoplado a la proteína g
UY38367A (es) * 2018-09-13 2020-04-30 Syngenta Participations Ag Compuestos de azol-amida pesticidamente activos
CN114181276A (zh) * 2021-12-17 2022-03-15 安徽大学 硫酯肽合成方法

Family Cites Families (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4200750A (en) 1977-01-07 1980-04-29 Westwood Pharmaceuticals Inc. 4-Substituted imidazo [1,2-a]quinoxalines
JPS6480026A (en) 1987-09-21 1989-03-24 Mitsubishi Electric Corp Resist coater
DE4102024A1 (de) * 1991-01-24 1992-07-30 Thomae Gmbh Dr K Biphenylderivate, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
TW432061B (en) 1994-08-09 2001-05-01 Pfizer Res & Dev Lactams
US6069143A (en) * 1994-12-20 2000-05-30 Smithkline Beecham Corporation Fibrinogen receptor antagonists
AU4064597A (en) 1996-08-16 1998-03-06 Du Pont Pharmaceuticals Company Amidinophenyl-pyrrolidines, -pyrrolines, and -isoxazolidines and derivatives thereof
WO2003062252A1 (en) * 2002-01-18 2003-07-31 Merck & Co., Inc. Edg receptor agonists
WO2003062248A2 (en) 2002-01-18 2003-07-31 Merck & Co., Inc. N-(benzyl)aminoalkylcarboxylates, phosphinates, phosphonates and tetrazoles as edg receptor agonists
WO2003061567A2 (en) 2002-01-18 2003-07-31 Merck & Co., Inc. Selective s1p1/edg1 receptor agonists
JP2005531506A (ja) 2002-03-01 2005-10-20 メルク エンド カムパニー インコーポレーテッド Edg受容体作動薬としてのアミノアルキルホスホネートおよび関連化合物
MXPA04010379A (es) * 2002-04-23 2005-02-17 Squibb Bristol Myers Co Compuestos de pirrolo-triazina anilina utiles como inhibidores de cinasa.
CA2488117A1 (en) 2002-06-17 2003-12-24 Merck & Co., Inc. 1-((5-aryl-1,2,4-oxadiazol-3-yl)benzyl)azetidine-3-carboxylates and 1-((5-aryl-1,2,4-oxadiazol-3-yl)benzyl)pyrrolidine-3-carboxylates as edg receptor agonists
AU2003279915A1 (en) 2002-10-15 2004-05-04 Merck And Co., Inc. Process for making azetidine-3-carboxylic acid
CA2509218C (en) 2002-12-20 2010-09-07 Merck & Co., Inc. 1-(amino)indanes and (1,2-dihydro-3-amino)-benzofurans, benzothiophenes and indoles as edg receptor agonists
BRPI0407401A (pt) 2003-02-11 2006-02-21 Irm Llc compostos bicìclicos e composições
CA2524867A1 (en) 2003-05-15 2004-12-02 Merck & Co., Inc. 3-(2-amino-1-azacyclyl)-5-aryl-1,2,4-oxadiazoles as s1p receptor agonists
MXPA05012460A (es) 2003-05-19 2006-05-25 Irm Llc Compuestos y composiciones inmunosupresoras.
SI1638551T1 (sl) 2003-05-19 2012-04-30 Irm Llc Imunosupresivne spojine in sestavki
MY150088A (en) 2003-05-19 2013-11-29 Irm Llc Immunosuppressant compounds and compositions
MXPA05012461A (es) 2003-05-19 2006-02-22 Irm Llc Compuestos y composiciones inmunosupresores.
CA2539438A1 (en) 2003-10-01 2005-04-14 Merck And Co., Inc. 3,5-aryl, heteroaryl or cycloalkyl substituted-1,2,4-oxadiazoles as s1p receptor agonists
AU2004299456B2 (en) 2003-12-17 2010-10-07 Merck Sharp & Dohme Corp. (3,4-disubstituted)propanoic carboxylates as S1P (Edg) receptor agonists
TW200538433A (en) 2004-02-24 2005-12-01 Irm Llc Immunosuppressant compounds and compositiions
EP1804793A4 (en) 2004-10-22 2010-03-31 Merck Sharp & Dohme 2- (ARYL) AZACYCLYLMETHYL-CARBOXYLATE, SULPHONATE, PHOSPHONATE, PHOSPHINATE AND HETEROCYCLES AS S1P RECEPTOR AGONISTS
CA2596990A1 (en) 2005-02-14 2006-08-24 University Of Virginia Patent Foundation Sphingosine 1-phosphate agonists comprising cycloalkanes and 5 -membered heterocycles substituted by amino and phenyl groups
PT1863474E (pt) 2005-03-23 2009-01-20 Actelion Pharmaceuticals Ltd Novos derivados de tiofeno como agonistas dos receptores 1 de esfingosina-1-fosfato
PT1863787E (pt) 2005-03-23 2011-07-29 Actelion Pharmaceuticals Ltd Derivados de benzo(c)tiofenos hidrogenados como imunomoduladores
TW200642683A (en) 2005-04-22 2006-12-16 Sankyo Co Heterocyclic compound
MX2007015422A (es) 2005-06-08 2008-02-21 Novartis Ag Oxadiazoles o isoxazoles policiclicos y su uso como ligandos del receptor de s1p.
RU2008101805A (ru) 2005-06-24 2009-07-27 Актелион Фармасьютиклз Лтд (Ch) Новые производные тиофена
AU2006283175A1 (en) 2005-08-23 2007-03-01 Irm Llc Immunosuppressant compounds and compositions
TW200800911A (en) 2005-10-20 2008-01-01 Biolipox Ab Pyrazoles useful in the treatment of inflammation
WO2007061458A2 (en) * 2005-11-23 2007-05-31 Epix Delaware, Inc. S1p receptor modulating compounds and use thereof
TWI404706B (zh) 2006-01-11 2013-08-11 Actelion Pharmaceuticals Ltd 新穎噻吩衍生物
GB0601744D0 (en) 2006-01-27 2006-03-08 Novartis Ag Organic compounds
TW200806611A (en) 2006-02-09 2008-02-01 Daiichi Seiyaku Co Novel amidopropionic acid derivatives and medicine containing the same
TW200806633A (en) * 2006-03-21 2008-02-01 Epix Pharm Inc S1P receptor modulating compounds and use thereof
BRPI0709866B8 (pt) 2006-04-03 2021-05-25 Astellas Pharma Inc compostos héteros e composição farmacêutica compreendendo ditos compostos
EP2046766A1 (en) 2006-08-01 2009-04-15 Praecis Pharmaceuticals Incorporated Agonists of the sphingosine- 1- phosphate receptor (slp)
JP2009269819A (ja) * 2006-08-25 2009-11-19 Asahi Kasei Pharma Kk アミン化合物
MX2009002233A (es) 2006-09-07 2009-03-16 Actelion Pharmaceuticals Ltd Derivados de piridin-4-il como agentes inmunomoduladores.
AR061841A1 (es) 2006-09-07 2008-09-24 Actelion Pharmaceuticals Ltd Derivados de tiofen-oxadiazoles, agonistas del receptor s1p1/edg1, composiciones farmaceuticas que los contienen y usos como agentes inmunomoduladores.
BRPI0716815A2 (pt) 2006-09-07 2013-11-05 Allergan Inc Co posto heteroatomáticos tendo atividade biológia agonista e/ou antagonista de receptor de esfinfosina-1-fosfato (s1p)
JP5253400B2 (ja) * 2006-09-08 2013-07-31 アクテリオン ファーマシューティカルズ リミテッド 免疫調節薬としてのピリジン−3−イル誘導体
JP2010502675A (ja) 2006-09-08 2010-01-28 ノバルティス アクチエンゲゼルシャフト リンパ球相互作用が介在する疾患または障害を処置するために有用なn−ビアリール(ヘテロ)アリールスルホンアミド誘導体
CN101522645B (zh) 2006-09-21 2013-01-09 埃科特莱茵药品有限公司 苯衍生物及其免疫调节剂的用途
BRPI0717656A2 (pt) 2006-09-29 2014-04-29 Novartis Ag Derivados de diaril oxadiazol
CA2669102A1 (en) 2006-11-21 2008-05-29 University Of Virginia Patent Foundation Tetralin analogs having sphingosine 1-phosphate agonist activity
CA2672616A1 (en) 2006-12-15 2008-06-26 Abbott Laboratories Novel oxadiazole compounds
GB0625648D0 (en) 2006-12-21 2007-01-31 Glaxo Group Ltd Compounds
JP2010513532A (ja) 2006-12-21 2010-04-30 アボット・ラボラトリーズ スフィンゴシン−1−ホスフェート受容体作働薬および拮抗薬化合物
JO2701B1 (en) 2006-12-21 2013-03-03 جلاكسو جروب ليميتد Vehicles
WO2008091967A1 (en) 2007-01-26 2008-07-31 Smithkline Beecham Corporation Chemical compounds
AU2008227979B2 (en) 2007-03-16 2014-02-06 Actelion Pharmaceuticals Ltd Amino- pyridine derivatives as S1P1 /EDG1 receptor agonists
AR066095A1 (es) * 2007-04-19 2009-07-22 Glaxo Group Ltd Compuesto de oxadiazol su uso para preparar un medicamento composicion farmaceutica que lo comprende y procedimiento para prepararla
WO2009011850A2 (en) 2007-07-16 2009-01-22 Abbott Laboratories Novel therapeutic compounds
CN101815707B (zh) 2007-10-04 2015-09-02 默克雪兰诺有限公司 噁二唑二芳基化合物
WO2009043889A2 (en) 2007-10-04 2009-04-09 Merck Serono S.A. Oxadiazole derivatives
CN101970430B (zh) 2007-11-01 2013-05-08 埃科特莱茵药品有限公司 嘧啶衍生物
US8202856B2 (en) 2007-12-21 2012-06-19 Merck Serono Sa Triazole oxadiazoles derivatives
DK2291080T3 (en) 2008-05-14 2015-12-07 Scripps Research Inst Novel modulator of sphingosinphosphatreceptorer
WO2010041655A1 (ja) 2008-10-06 2010-04-15 昭和電工株式会社 触媒およびその製造方法ならびにその用途
WO2010065760A1 (en) * 2008-12-04 2010-06-10 Exelixis, Inc. Imidazo [1,2a] pyridine derivatives, their use as s1p1 agonists and methods for their production
KR101589332B1 (ko) 2008-12-05 2016-01-27 아스텔라스세이야쿠 가부시키가이샤 2h-크로멘 화합물 및 그의 유도체
US8741923B2 (en) 2008-12-18 2014-06-03 Merck Serono Sa Oxadiazole fused heterocyclic derivatives useful for the treatment of multiple sclerosis
AR075319A1 (es) 2008-12-23 2011-03-23 Novartis Ag Compuestos de biaril- bencil-amina, procesos para su produccion, su uso como productos farmaceuticos, y composiciones farmaceuticas que los comprenden
EP2202232A1 (en) 2008-12-26 2010-06-30 Laboratorios Almirall, S.A. 1,2,4-oxadiazole derivatives and their therapeutic use
EP2210890A1 (en) 2009-01-19 2010-07-28 Almirall, S.A. Oxadiazole derivatives as S1P1 receptor agonists
WO2010085582A1 (en) 2009-01-23 2010-07-29 Bristol-Myers Squibb Company Substituted oxadiazole derivatives as s1p agonists in the treatment of autoimmune and inflammatory diseases
US8389509B2 (en) 2009-01-23 2013-03-05 Bristol-Myers Squibb Company Substituted pyrazole compounds
WO2010085581A1 (en) 2009-01-23 2010-07-29 Bristol-Myers Squibb Company Substituted oxadiazole derivatives as s1p agonists in the treatment of autoimmune and inflammatory diseases
JP5669363B2 (ja) 2009-03-31 2015-02-12 昭和電工株式会社 樹脂組成物及びこれで処理された紙又は繊維加工品
WO2010113528A1 (en) 2009-04-03 2010-10-07 Panasonic Corporation Mobile communication method, mobile communication system, and corresponding apparatus

Also Published As

Publication number Publication date
AR077819A1 (es) 2011-09-28
TW201109323A (en) 2011-03-16
JP2013501729A (ja) 2013-01-17
EA201270266A1 (ru) 2012-07-30
KR20120108963A (ko) 2012-10-05
ES2533095T3 (es) 2015-04-07
JP5602230B2 (ja) 2014-10-08
US20110190255A1 (en) 2011-08-04
SG177691A1 (en) 2012-02-28
PE20120732A1 (es) 2012-06-20
CL2012000326A1 (es) 2012-10-19
EP2462139A1 (en) 2012-06-13
US8399451B2 (en) 2013-03-19
CA2770194A1 (en) 2011-02-10
MX2012001160A (es) 2012-02-13
WO2011017578A1 (en) 2011-02-10
CN102548989A (zh) 2012-07-04
EP2462139B1 (en) 2015-01-14
ZA201200641B (en) 2013-06-26
AU2010279354A1 (en) 2012-02-09
BR112012002824A2 (pt) 2019-09-24

Similar Documents

Publication Publication Date Title
CO6430439A2 (es) Agonistas del receptor de esfingosina -1- fosfato
NI201100100A (es) Moduladores de aril metil benzoquinazolinona alostéricos positivos del receptor m1.
CU20110216A7 (es) Derivados aminobutíricos sustituidos como inhibidores de neprilisina
AR069490A1 (es) Agonistas de los receptores de glucocorticoides
UY30414A1 (es) Metano sulfonatos, propano-1-sulfonatos y ciclopropan sulfonatos sustituidos con [2,3,4,8-tetrahidroimidazo-[1,5-al-pirimidin-8-il]-fenilo, composiciones farmacéuticas conteniéndolos y aplicaciones.
EA200971107A1 (ru) Катехоламиновые производные, полезные для лечения болезни паркинсона
EA201071040A1 (ru) Новые производные 1-бензил-3-гидроксиметилиндазола и их применение при лечении заболеваний, обусловленных экспрессией mcp-1, cx3cr1 и p40
RU2013121788A (ru) Ингибиторы репликации вич
EA200970928A1 (ru) Антагонисты рецептора гонадотропин-рилизин-фактора и способы их применения
CU20110217A7 (es) Derivados amino-propiónicos sustituidos como inhibidores de neprilisina
CL2009000815A1 (es) Compuestos derivados de fenilhidroximetilpirrolidina, agonista del recptor adrenergico beta 3; composicion farmaceutica que los comprende; uso en el tratamiento de vejiga hiperactiva, incontinencia urinaria por impulso y urgencia urinaria.
EA201390840A1 (ru) Полициклический lpaантагонист и его применение
BRPI0718714B8 (pt) arilamidas substituídas por tiazol e oxazol, seu uso e composição farmacêutica que as compreende
CY1108690T1 (el) Υποκατεστημενες ν-αρυλοπυρρολιδινες ως επιλεκτικοι διαμορφωτες υποδοχεα ανδρογονων
BRPI0517425A (pt) composto ou um sal, solvato, enanciÈmero, diastereÈmero ou mistura de diastereÈmeros do mesmo, composição farmacêutica, uso de composto
EA201171109A1 (ru) Новая композиция замедленного высвобождения соединений, выбранных из класса миорелаксантов центрального действия
EA201290394A1 (ru) Морфолинотиазолы в качестве позитивных аллостерических модуляторов альфа 7
MX2012004848A (es) Compuestos heterociclicos triciclicos.
AR050914A1 (es) Agonista receptor de vasopresina peptidico
UY31554A1 (es) Nuevos inhibidores de acetil coenzima a carboxilasa y usos en tratamientos de obesidad y diabetes mellitus
EA201400067A1 (ru) Новая терапевтическая композиция, содержащая апоморфин в качестве активного ингредиента
AR054508A1 (es) Compuesto de bencilpiperazina, su uso para preparar un medicamento, procedimientos para la preparacion de dicho compuesto y de compuestos intermediarios, dichos compuestos intermediarios, composicion farmaceutica que lo comprende y procedimiento para prepararla
PE20081703A1 (es) Nuevos derivados triciclicos, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen
AR119614A1 (es) Formas en estado sólido de (s)-2-(((s)-6,8-diflúor-1,2,3,4-tetrahidronaftalen-2-il)amino)-n-(1-(2-metil-1-(neopentilamino)propan-2-il)-1h-imidazol-4-il)pentanamida y usos de la misma
UY31672A1 (es) "agonistas de receptores muscarínicos composiciones farmacéuticas métodos de tratamiento de los mismos, y procedimientos para su preparación"

Legal Events

Date Code Title Description
FC Application refused